RESUMO
Diabetic nephropathy(DN) is one of the most common microvascular complications of Diabetes mellitu. It is one of the leading causes of End-stage renal diseae(ESRD). The pathogenesis of DN is complex and difficult to treat. In recent years, Sodium-glucose cotransport 2 (SGLT-2) inhibitors have become a research hotspot in the treatment of DN. They could effectively lower blood glucose, improve renal hyperfiltration and hypoxia, reduce urinary protein, weight, blood pressure and uric acid. In addition, SGLT2 is also anti-inflammatory and antioxidative, etc. This article reviews the progress of SGLT-2 inhibitors in 3 aspects, including the hypoglycemic characteristics, the protective effects of SGLT-2 inhibitors on the kidney, as well as the adverse reactions of SGLT-2 inhibitors.
RESUMO
The aim of this study is to investigate the influence of flufenamic acid (FFA) on the solubility, dissolution and bioavailability of sorafenib (SFN) in the combined administration of the MSNM@SFN and FFA. The MSNM@SFN&FFA was prepared by mixing the MSNM@SFN with FFA. The solubility, dissolution and bioavailability of SFN in the MSNM@SFN&FFA complex was investigated in comparison with those of the MSNM@SFN. This study was performed following the National Institutes of Health guidelines for the use of experimental animals; all care and handling of animals were performed with the approval of the Experimental Animal Center of Peking University Health Science Center. The MSNM@SFN&FFA showed no significant influence on the solubility, dissolution and bioavailability of SFN when compared with the MSNM@SFN. These data indicated that FFA had almost no influence on the solubility, dissolution and bioavailability of SFN in the combined administration of MSNM@SFN and FFA, thus providing an experimental foundation for the subsequent formulation research on the combined usage of drugs.